FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagede.medizininformatikinitiative.kerndatensatz.mtb
Resource TypeCarePlan
IdCarePlan-mii-exa-mtb-kim-musterperson-therapieplan.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source


English


Generated Narrative: CarePlan mii-exa-mtb-kim-musterperson-therapieplan

Profile: MII PR MTB Therapieplan version: 2027.0.0-ballot.1

status: Active

intent: Plan

category: prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie)

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-03-28

addresses: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

supportingInfo: ClinicalImpression: status = completed; effective[x] = 2023-01-20 --> 2023-03-28

activity

outcomeReference: Procedure Chemotherapy

reference: MedicationRequest: extension = 1,Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: MedicationRequest: extension = 3,Predictive value of the biomarker or clinical effectiveness of the drug in a molecularly stratified cohort was demonstrated in a retrospective cohort or case–control study in the same tumor type.,http://www.ncbi.nlm.nih.gov/pubmed#35665782,http://www.ncbi.nlm.nih.gov/pubmed#37870536,http://doi.org#10.1200/JCO.2023.41.17_suppl.LBA3000; status = draft; intent = proposal; medication[x] = Trastuzumab deruxtecan; authoredOn = 2023-03-28

activity

reference: RequestGroup Chemotherapie + zielgerichtete Substanzen

activity

reference: RequestGroup zielgerichtete Substanzen

activity

reference: MedicationRequest: extension = 6,Preclinical data (in vitro, in vivo models or functional genomics studies) demonstrate that the biomarker predicts response to a specific drug treatment, supported by scientific rationale.,http://www.ncbi.nlm.nih.gov/pubmed#31209687; status = draft; intent = option; medication[x] = COBIMETINIB; authoredOn = 2023-03-28

activity

reference: ServiceRequest Genetic consultation (procedure)

activity

reference: ServiceRequest Refer for histology (procedure)

activity

reference: ServiceRequest Biopsy (procedure)


German


Generated Narrative: CarePlan mii-exa-mtb-kim-musterperson-therapieplan

Profile: MII PR MTB Therapieplan version: 2027.0.0-ballot.1

status: Active

intent: Plan

category: prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie)

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-03-28

addresses: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

supportingInfo: ClinicalImpression: status = completed; effective[x] = 2023-01-20 --> 2023-03-28

activity

outcomeReference: Procedure Chemotherapy

reference: MedicationRequest: extension = 1,m1A,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: MedicationRequest: extension = 3,m1B,http://www.ncbi.nlm.nih.gov/pubmed#35665782,http://www.ncbi.nlm.nih.gov/pubmed#37870536,http://doi.org#10.1200/JCO.2023.41.17_suppl.LBA3000; status = draft; intent = proposal; medication[x] = Trastuzumab deruxtecan; authoredOn = 2023-03-28

activity

reference: RequestGroup Chemotherapie + zielgerichtete Substanzen

activity

reference: RequestGroup zielgerichtete Substanzen

activity

reference: MedicationRequest: extension = 6,m3,http://www.ncbi.nlm.nih.gov/pubmed#31209687; status = draft; intent = option; medication[x] = COBIMETINIB; authoredOn = 2023-03-28

activity

reference: ServiceRequest Genetic consultation (procedure)

activity

reference: ServiceRequest Refer for histology (procedure)

activity

reference: ServiceRequest Biopsy (procedure)


Source1

{
  "resourceType": "CarePlan",
  "id": "mii-exa-mtb-kim-musterperson-therapieplan",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieplan|2027.0.0-ballot.1"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "active",
  "intent": "plan",
  "category": [
    {
      "coding": [
        {
          "system": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ",
          "code": "praeth"
        }
      ]
    }
  ],
  "subject": {
    "reference": "Patient/PatientKimMusterperson"
  },
  "created": "2023-03-28",
  "addresses": [
    {
      "reference": "Condition/PatientKimMusterperson-PrimaryDiagnosis-2"
    }
  ],
  "supportingInfo": [
    {
      "reference": "ClinicalImpression/mii-exa-mtb-kim-musterperson-behandlungsepisode"
    }
  ],
  "activity": [
    {
      "outcomeReference": [
        {
          "reference": "Procedure/MTBChemo2Procedure"
        }
      ],
      "reference": {
        "reference": "MedicationRequest/mii-exa-mtb-medication-request-mirvetuximab"
      }
    },
    {
      "reference": {
        "reference": "ServiceRequest/mii-exa-mtb-study-request-cldn6"
      }
    },
    {
      "reference": {
        "reference": "ServiceRequest/mii-exa-mtb-study-request-tedova"
      }
    },
    {
      "reference": {
        "reference": "ServiceRequest/mii-exa-mtb-study-request-ccne1"
      }
    },
    {
      "reference": {
        "reference": "MedicationRequest/mii-exa-mtb-medication-request-trastuzumab-deruxtecan"
      }
    },
    {
      "reference": {
        "reference": "RequestGroup/mii-exa-mtb-request-group-adavosertib-carboplatin"
      }
    },
    {
      "reference": {
        "reference": "RequestGroup/mii-exa-mtb-request-group-lunresertib-camonsertib"
      }
    },
    {
      "reference": {
        "reference": "MedicationRequest/mii-exa-mtb-medication-request-cobimetinib"
      }
    },
    {
      "reference": {
        "reference": "ServiceRequest/mii-exa-mtb-kim-humangenetische-beratung-aszites"
      }
    },
    {
      "reference": {
        "reference": "ServiceRequest/mii-exa-mtb-kim-histologie-evaluation-aszites"
      }
    },
    {
      "reference": {
        "reference": "ServiceRequest/mii-exa-mtb-kim-rebiopsie-aszites"
      }
    }
  ]
}